Publications
Publications
- January 2021 (Revised March 2021)
- HBS Case Collection
Serum Institute of India (SII): Racing to Save Lives During a Pandemic
By: Rohit Deshpandé, Anjali Raina and Rachna Chawla
Abstract
The CEO of Serum Institute of India (SII), a $12.8 billion Indian Family business is faced with a risky choice between principles and profit. SII is the largest manufacturer of vaccines in the world and Adar Poonawalla, the CEO and son of the founder has to decide how to temper his responsibility to meet the world's need for an affordable, efficacious and safe COVID-19 vaccine with his need to maintain profitability.
Keywords
Business Ethics; Healthcare; COVID-19; Vaccines; Family Business; Ethics; Health Care and Treatment; Health Pandemics; Leadership; Corporate Accountability; Fairness; Growth and Development Strategy; Health Industry; India; South Asia
Citation
Deshpandé, Rohit, Anjali Raina, and Rachna Chawla. "Serum Institute of India (SII): Racing to Save Lives During a Pandemic." Harvard Business School Case 521-028, January 2021. (Revised March 2021.)
About The Author
